Paper39474397
Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.
Wang YQ and 9 others. World J Gastroenterol, 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. Papers, record 39474397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39474397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Body Mass Index | Major topic |
| Phenylurea Compounds | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Quinolines | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Retrospective Studies | |
| Prognosis | |
| Aged | |
| Obesity | |
| Neoplasm Staging | |
| Adult | |
| Treatment Outcome | |
| Progression-Free Survival | |
| Hepatitis B | |
| Overweight |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 2 | 34880251 | Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. | Nat Commun | 2021 | https://conductscience.org/library/papers/34880251 | PubMed |
| 3 | 37598406 | Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. | Int J Surg | 2023 | https://conductscience.org/library/papers/37598406 | PubMed |
| 4 | 29577028 | Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study. | J Clin Transl Hepatol | 2018 | https://conductscience.org/library/papers/29577028 | PubMed |
| 5 | 15199035 | Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. | JAMA | 2004 | https://conductscience.org/library/papers/15199035 | PubMed |
| 6 | 29972759 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29972759 | PubMed |
| 7 | 31876896 | Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/31876896 | PubMed |
| 8 | 28130846 | AASLD guidelines for the treatment of hepatocellular carcinoma. | Hepatology | 2018 | https://conductscience.org/library/papers/28130846 | PubMed |
| 9 | 29449192 | Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29449192 | PubMed |
| 10 | 34976804 | The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study. | Front Oncol | 2021 | https://conductscience.org/library/papers/34976804 | PubMed |
| 11 | 20207633 | Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. | Gut | 2010 | https://conductscience.org/library/papers/20207633 | PubMed |
| 12 | 15051297 | Appropriate BMI for Asian populations. | Lancet | 2004 | https://conductscience.org/library/papers/15051297 | PubMed |
| 13 | 30882850 | The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy. | JAMA | 2019 | https://conductscience.org/library/papers/30882850 | PubMed |
| 14 | 35982962 | Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study. | Front Oncol | 2022 | https://conductscience.org/library/papers/35982962 | PubMed |
| 15 | 20175765 | Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. | Aliment Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20175765 | PubMed |
| 16 | 35379737 | Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35379737 | PubMed |
| 17 | 22446023 | Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. | Eur J Cancer | 2012 | https://conductscience.org/library/papers/22446023 | PubMed |
| 18 | 30273398 | Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. | PLoS One | 2018 | https://conductscience.org/library/papers/30273398 | PubMed |
| 19 | 12365956 | Prevalence and trends in overweight among US children and adolescents, 1999-2000. | JAMA | 2002 | https://conductscience.org/library/papers/12365956 | PubMed |
| 20 | 31069144 | Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/31069144 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882861 | Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882861 | PubMed |
| 42851698 | Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42851698 | PubMed |
| 41810107 | Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/41810107 | PubMed |
| 41675519 | Global, regional, and national burden of liver cancer attributable to high BMI, 1990-2021, with future projections to 2040. | Front Oncol | 2025 | https://conductscience.org/library/papers/41675519 | PubMed |
| 41546382 | Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study. | Oncologist | 2026 | https://conductscience.org/library/papers/41546382 | PubMed |
| 41267926 | Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41267926 | PubMed |
| 41236792 | Prognostic Impact of Body Mass index in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: An Updated Systematic Review and Meta-Analysis. | Technol Cancer Res Treat | 2025 | https://conductscience.org/library/papers/41236792 | PubMed |
| 40497086 | Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/40497086 | PubMed |
| 40308633 | Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy. | Front Nutr | 2025 | https://conductscience.org/library/papers/40308633 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39474397
GET https://conductscience.org/api/papers/v1/39474397/references?page=2